Asset
ALDOXORUBICIN
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01580397 | phase2 | completed | 2012-05-16 | 2013-05-13 | ImmunityBio, Inc. | Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer |
| NCT01514188 | phase2 | completed | 2012-01-11 | 2014-04-09 | ImmunityBio, Inc. | Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma |
| NCT01337505 | phase1 | completed | 2011-04-01 | 2012-09-01 | ImmunityBio, Inc. | Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors |
FDA applications (0)
This company has no applications containing this asset.